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Abstract 
Treatment  related  myelodysplastic  syn-
drome (t-MDS) and acute myeloid leukemia
(t-AML)  are  well  known  complications  after
chemotherapy  for  various  hematologic  and
non-hematologic  malignancies.  Alkylating
agents and Topoisomerase inhibitors are most
widely studied in this regard. There is growing
concern  about  occurrence  of  t-MDS,  t-
MDS/AML and t-AML in patients of CLL treat-
ed  with  nucleoside  analogues  especially  in
combination  with  alkylating  agents.  Exact
incidence  and  pathogenesis  of  nucleoside
analogue related MDS/AML is not clear at this
time. We hereby report a case of t-AML in a
patient  treated  with  Fludarabine,
Cyclophosphamide and Rituximab (FCR) for
CLL.  The  cytogenetic  studies  revealed  a
unique translocation t (10:16), that has been
reported in very few cases of therapy related
AML and pediatric AML.
Introduction
Occurrence of second malignancies is a well-
documented phenomenon in chronic lymphocyt-
ic  leukemia  (CLL).  Disease  related  immune
deficiency  and  decreased  immunosurveillance
is purposed as one of the mechanisms related to
these second malignancies.1Recent advances in
CLL treatment have led to better remission rates
and prolonged survival in CLL patients. At the
same time treatment related late onset toxicities
such as therapy related t-MDS, MDS /AML and
AML  have  been  reported  in  some  cases.  We
hereby report a case of t-AML with t (10:16) aris-
ing in patient treated with FCR regimen for CLL.
To the best of our knowledge this is the first case
of t-AML with t (10:16) in a patient of CLL treat-
ed with Fludarabine and Cyclophosphamide.
Case Report
This patient is an 83-year-old male who was
diagnosed with CLL in 2007. He received six
cycles of Fludarabine, Cyclophosphamide and
Rituximab  from  September  2007  to  March
2008.  Due  to  his  co-morbities,  attenuated
doses were used and a 10% dose reduction was
done for Fludarabine and Cyclophosphamide.
Off  therapy,  he  had  stable  cytopenias  in  all
three cell lines. In June 2011, he presented
with increasing White Blood Cell (WBC) count
and  thrombocytopenia.  A  clinical  differential
diagnosis of CLL relapse versus a prolympho-
cytic  transformation  versus  myelodysplastic
syndrome was made. At the time of presenta-
tion his CBC findings were as follows: WBC
count  30.7/MM3,  hemoglobin  9.4  gm/dL  and
platelet count 19/KMM3. The peripheral blood
smear showed numerous small lymphoid cells
along with some large immature cells. These
immature  cells  showed  nuclei  with  fine
nuclear chromatin, 1-3 prominent nucleoli and
mild  to  moderate  amount  of  blue  grey  cyto-
plasm.  Some  of  the  cells  showed  nuclear
indentation,  nuclear  membrane  folding  and
fine cytoplasmic vacuolation. On flow cytome-
try,  two  distinct  populations  were  observed;
one in the lymphocytic gate and the second in
the monocytic gate (Figure 1). The population
in the lymphocytic gate showed co-expression
of  CD19,  CD20,  CD5,  CD23  and  kappa  light
chains. The cell population in the monocytic
gate was positive for expression of CD2, CD4,
CD33 and CD64. These cells showed lack of
expression of CD14, CD16, CD34, CD117 and
HLA-DR.  The  bone  marrow  aspirate  smears
were predominantly composed of blasts (50%
of the all nucleated cells) and mature lymphoid
cells (30% of the all nucleated cells) (Figure
2). The bone marrow biopsy findings included
a hypercellular marrow with marked suppres-
sion  of  trilineage  hematopoiesis  and  aggre-
gates  of  mature  looking  lymphocytes  amidst
sheets  of  immature  blasts  (Figure  3).  This
case  was  diagnosed  as  AML  with  monocytic
features arising in background of CLL. He was
started on Azacytidine then. The cytogenetic
findings  were  as  follows:  46XY,
der(4)t(4:16)(p14:q22),  inv(6)  (p23:q15),
t(10:16)(q22:p13.3),del(20q)  (q11.2q13.1).
t(10:16)  and  del(20q)  were  observed  in  all
twenty metaphases analyzed. 
Discussion
The clinical course of CLL can be complicat-
ed  by  transformation  to  a  prolymphocytic
leukemia,  diffuse  large  B-cell  lymphoma
(Richter’s  transformation)  and  rarely  even
acute  lymphoblastic  leukemia.1 With  the
recent  advances  in  the  treatment  of  Non-
Hodgkin Lymphomas, the remission and over-
all survival rates have markedly improved in
patients with CLL. With prolonged survival, the
late effects of therapy are becoming more evi-
dent and hence more amenable to study.
Two  subtypes  of  therapy  related  myeloid
neoplasms (t-MN) are described in WHO clas-
sification of hematopoietic neoplasms. The t-
MN occurring after administration of alkylat-
ing agents occurs after long latent period of 5-
10 years; frequently present with cytopenias,
myelodysplasia and abnormalities of chromo-
some 5 and 7. On the other hand t-MN related
to  the  Topoisomerase  Inhibitors  frequently
present with overt leukemia without preceding
MDS and is more commonly associated with
balanced  translocations.2 t-MN  related  to
purine  analogues  such  as  Fludarabine  and
Cladribine  have  been  infrequently  reported.
Accurate incidence and clinicopathologic fea-
tures  of  this  group  of  patients  are  not  well
described in the literature.  
The  relative  contributions  of  chemothera-
peutic  interventions  in  the  onset  of  t-
MDS/AML  associated  with  nucleoside  ana-
logues are not well defined. Some authors have
reported  increased  risk  of  MDS/AML  when
nucleoside analogues are used in combination
with alkylating agents.3 Fludarabine has been
reported  to  augment  the  cytotoxic  damage
caused by alkylating agents.4
The CALGB9011 study reported an incidence
of 3.5% in patients who were treated with both
Fludarabine  and  Chlorambucil,  0.5%  with
Fludarabine  alone  and  0%  in  Chlorambucil
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alone.5 Recently Kluk et al. reported a series of
five patients of t-MDS/AML (MDS=3, AML=2)
who were treated with Fludarabine (n=4) and
Fludarabine  with  rituximab  (n=-1)  for  CLL
(n=4)  and  marginal  zone  lymphoma  (n=1).
They  compared  these  patients  to  a  control
group  of  15  patients  who  were  only  treated
with  alkylating  agents  and  reported  a  short
latency  period,  less  likely  tendency  to  show
complex  karyotypes  and  longer  median  sur-
vival  in  patients  treated  with  Fludarabine
alone.6 Čolović et  al. reported  retrospective
analysis of 210 CLL patients who were treated
with Fludarabine and Cyclophosphamide. They
reported t-MDS/AML in 4/210 (1.9%) patients
which is slightly less than in other studies.7
Tam et al reported results of FCR (Fludarabine,
Cyclophosphamide and Rituximab) treatment
for CLL. Out of 300 patients, 8 patients devel-
oped MDS/AML.8
The  risk  factors  for  developing  t-AML  or
MDS or MDS/AML are not well defined. There
is emerging role of genetic predisposing fac-
tors. Larson has previously reported increased
frequency  of  NQO1  gene  polymorphisms  in
patients with t-MN.9 Other reported risk fac-
tors  for  occurrence  of  t-MDS/AML  in  CLL
patients  include:  paratrabecular  pattern  of
bone marrow infiltration by lymphoma, treat-
ment with Rituximab, prolonged bi/pan cytope-
nias  and  hypocellular  marrow  after
Fludarabine treatment.10
Various  cytogenetic  complex  karyotypes
have been reported in t-MDS/AML in CLL. The
most frequently reported are del (5) (q13q33),
del (7), +3mar (cp20), +mar (13) and multiple
other aberrations of chromosome 8, 11, 15 and
17.11  Cytogenetic  findings  in  our  patient
revealed del (20q) and an unusual findings of
t (10:16).
While del (20q) is a common findings in t-
MDS/AML, t (10:16) is rare rearrangement that
has been reported in very few cases of AML-
M4/M5.12 In t (10:16), the monocytic leukemia
Zinc finger protein related factor (MORF) at
10q22 has been shown to fuse with CREB bind-
ing  protein  (CBP)  gene  at  16p13.  MORF
resembles  monocytic  leukemia  zinc  finger
(MOZ) gene.12,13 Cases of MOZ-CBP fusion t
(8:16) have shown to be associated with mono-
cytic differentiation.14 However role of MORF-
CBP fusion gene in leukemogenesis is not well
studied in the literature. To the best of our
knowledge only 5 cases have been reported so
far. Pebusque et al reported a case of AML-M4
in patient with two reciprocal translocations
involving t (11:17) and t (10:16).15 Later on
Panagopoulos et al reported a case of AML-5a
in a 4-year-old girl with a complex karyotype
including t (10:16)(q22;p13).16 Another case of
AML with t (10:16) was reported in an 84-year-
old male with AML-M4.17 Interestingly Kojima
et al reported a case of 52-year-old female who
was diagnosed with AML with t (10:16) after
prolonged  preleukemic  phase  and  the  blasts
did not show evidence of monocytic differenti-
ation.18
Conclusions
Risk of therapy related MDS or AML is an
emerging problem in era of successful treat-
ment  of  many  hematologic  as  well  as  non-
hematologic malignancies. Our case is inter-
esting  and  educational  at  several  levels.  In
patients of CLL treated with nucleoside ana-
logues and or alkylating agents, who present
with various cytopenias or suspected transfor-
mation, a differential diagnosis of t-MN should
be kept in mind. This case also demonstrated
presence of a rare translocation, t (10:16). This
finding might be helpful in understanding the
pathogenesis of t-MN.  
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